Timothy S C Hinks1,2,3, Joshua C Wallington1, Anthony P Williams4,5, Ratko Djukanović1,2, Karl J Staples1,5, Tom M A Wilkinson1,2,5. 1. 1 Clinical & Experimental Sciences and. 2. 2 Southampton NIHR Respiratory Biomedical Research Unit, Southampton General Hospital, Southampton, United Kingdom. 3. 3 Department for Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia; and. 4. 4 Cancer Sciences, University of Southampton Faculty of Medicine, Sir Henry Wellcome Laboratories, Southampton General Hospital, Southampton, United Kingdom. 5. 5 Wessex Investigational Sciences Hub, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, United Kingdom.
Abstract
RATIONALE: Mucosal-associated invariant T (MAIT) cells are a recently described abundant, proinflammatory T-cell subset with unknown roles in pulmonary immunity. Nontypeable Haemophilus influenzae (NTHi) is the leading bacterial pathogen during chronic obstructive pulmonary disease (COPD) exacerbations and is a plausible target for MAIT cells. OBJECTIVES: To investigate whether MAIT cells respond to NTHi and the effects of inhaled corticosteroids (ICS) on their frequency and function in COPD. METHODS: Eleven subjects with COPD receiving ICS, 8 steroid-naive subjects with COPD, and 21 healthy control subjects underwent phlebotomy, sputum induction, bronchoalveolar lavage, and endobronchial biopsy. Pulmonary and monocyte-derived macrophages were cultured in vitro with NTHi. MEASUREMENTS AND MAIN RESULTS: Frequencies of Vα7.2+CD161+ MAIT cells, surface expression of the major histocompatibility complex-related protein 1 (MR1), and intracellular IFN-γ expression were measured by flow cytometry. MAIT-cell frequencies were reduced in peripheral blood of ICS-treated subjects with COPD (median 0.38%; interquartile range [IQR], 0.25-0.96) compared with healthy control subjects (1.8%; IQR, 1.4-2.5; P = 0.001) or steroid-naive patients with COPD (1.8%; IQR, 1.2-2.3; P = 0.04). MAIT cells were reduced in bronchial biopsies from subjects with COPD treated with steroids (0.73%; IQR, 0.46-1.3) compared with healthy control subjects (4.0%; IQR, 1.6-5.0; P = 0.02). Coculture of live NTHi increased macrophage surface expression of MR1 and induced IFN-γ from CD4 cells and CD8 cells, but most potently from MAIT cells (median IFN-γ-positive frequencies, 2.9, 8.6, and 27.6%, respectively). In vitro fluticasone and budesonide reduced MR1 surface expression twofold and decreased NTHi-induced IFN-γ secretion eightfold. CONCLUSIONS: MAIT cells are deficient in blood and bronchial tissue in steroid-treated, but not steroid-naive, COPD. NTHi constitutes a target for pulmonary MAIT-cell immune responses, which are significantly impaired by corticosteroids.
RATIONALE: Mucosal-associated invariant T (MAIT) cells are a recently described abundant, proinflammatory T-cell subset with unknown roles in pulmonary immunity. Nontypeable Haemophilus influenzae (NTHi) is the leading bacterial pathogen during chronic obstructive pulmonary disease (COPD) exacerbations and is a plausible target for MAIT cells. OBJECTIVES: To investigate whether MAIT cells respond to NTHi and the effects of inhaled corticosteroids (ICS) on their frequency and function in COPD. METHODS: Eleven subjects with COPD receiving ICS, 8 steroid-naive subjects with COPD, and 21 healthy control subjects underwent phlebotomy, sputum induction, bronchoalveolar lavage, and endobronchial biopsy. Pulmonary and monocyte-derived macrophages were cultured in vitro with NTHi. MEASUREMENTS AND MAIN RESULTS: Frequencies of Vα7.2+CD161+ MAIT cells, surface expression of the major histocompatibility complex-related protein 1 (MR1), and intracellular IFN-γ expression were measured by flow cytometry. MAIT-cell frequencies were reduced in peripheral blood of ICS-treated subjects with COPD (median 0.38%; interquartile range [IQR], 0.25-0.96) compared with healthy control subjects (1.8%; IQR, 1.4-2.5; P = 0.001) or steroid-naive patients with COPD (1.8%; IQR, 1.2-2.3; P = 0.04). MAIT cells were reduced in bronchial biopsies from subjects with COPD treated with steroids (0.73%; IQR, 0.46-1.3) compared with healthy control subjects (4.0%; IQR, 1.6-5.0; P = 0.02). Coculture of live NTHi increased macrophage surface expression of MR1 and induced IFN-γ from CD4 cells and CD8 cells, but most potently from MAIT cells (median IFN-γ-positive frequencies, 2.9, 8.6, and 27.6%, respectively). In vitro fluticasone and budesonide reduced MR1 surface expression twofold and decreased NTHi-induced IFN-γ secretion eightfold. CONCLUSIONS: MAIT cells are deficient in blood and bronchial tissue in steroid-treated, but not steroid-naive, COPD. NTHi constitutes a target for pulmonary MAIT-cell immune responses, which are significantly impaired by corticosteroids.
Authors: Daniel Drömann; Jan Rupp; Kristina Rohmann; Sinia Osbahr; Artur J Ulmer; Sebastian Marwitz; Kristina Röschmann; Mahdi Abdullah; Holger Schultz; Ekkehard Vollmer; Peter Zabel; Klaus Dalhoff; Torsten Goldmann Journal: Respir Res Date: 2010-05-31
Authors: Lucy J Walker; Yu-Hoi Kang; Matthew O Smith; Hannah Tharmalingham; Narayan Ramamurthy; Vicki M Fleming; Natasha Sahgal; Alistair Leslie; Ye Oo; Alessandra Geremia; Thomas J Scriba; Willem A Hanekom; Georg M Lauer; Olivier Lantz; David H Adams; Fiona Powrie; Eleanor Barnes; Paul Klenerman Journal: Blood Date: 2011-11-15 Impact factor: 22.113
Authors: Timothy Hinks; Xiaoying Zhou; Karl Staples; Borislav Dimitrov; Alexander Manta; Tanya Petrossian; Pek Lum; Caroline Smith; Jon Ward; Peter Howarth; Andrew Walls; Stephan D Gadola; Ratko Djukanović Journal: Lancet Date: 2015-02-26 Impact factor: 79.321
Authors: Dominik Hartl; Rabindra Tirouvanziam; Julie Laval; Catherine M Greene; David Habiel; Lokesh Sharma; Ali Önder Yildirim; Charles S Dela Cruz; Cory M Hogaboam Journal: J Innate Immun Date: 2018-02-13 Impact factor: 7.349
Authors: R F Hannaway; X Wang; M Schneider; S Slow; J Cowan; B Brockway; M R Schofield; X C Morgan; D R Murdoch; J E Ussher Journal: Clin Exp Immunol Date: 2019-10-24 Impact factor: 4.330